Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Grants Orphan Status to 8 APIs
June 8, 2020
- Minister Mentions First Half 2021 Goal for Coronavirus Vaccination Start
June 8, 2020
- ASEAN + 3 Ministers Vow to Work towards Smooth Drug Distribution amid COVID-19
June 8, 2020
- Saliva-Based COVID-19 PCR Tests Reimbursed for Cases within 9 Days of First Symptoms: MHLW
June 4, 2020
- Japan Eyes Coronavirus Vaccination Launch in First Half of 2021
June 3, 2020
- Label Updates Ordered for Uptravi, Plavix, Permitting Their Concomitant Use: MHLW
June 3, 2020
- Japan OKs Add’l Indications for Ofev, Xtandi/Erleada and More
June 1, 2020
- Oral Semaglutide Clears MHLW Panel, Now in Line for June Approval
June 1, 2020
- MHLW Panel Gives Blessing to 1st Triple Combo Therapy for Asthma; Humira Biosimilar Also in Line for June OK
May 29, 2020
- Japan Sets 30 Day Prescription Limit for Shionogi’s ADHD Med Vyvanse
May 29, 2020
- 145.5 Billion Yen Allocated for COVID-19 Vaccine Production in Second Extra Budget: MHLW
May 29, 2020
- GSK’s Cost-Effectiveness Analysis for Trelegy Delayed, First Product under Full CEA Scheme
May 28, 2020
- Chuikyo Wary about Off-Year Price Survey amid COVID-19, Industry Officials Stress Concerns
May 28, 2020
- Japan Drops May-End Goal for Avigan’s COVID-19 Approval
May 27, 2020
- Council to Discuss Medical Needs for Additional Indications for Antiemetics Ondansetron, Granisetron
May 27, 2020
- Japan’s First Humalog Biosimilar to Join NHI Price List on May 27
May 26, 2020
- Final Report from Govt’s All-Generation Social Security Council to Be Delayed until Year-End
May 26, 2020
- June Approval Likely for Entresto as It Clears Key Panel; HFpEF Use OK’ed Too
May 25, 2020
- Panel OKs Ofev for PF-ILD; Label Expansion for Xtandi/Erleada, Prevenar and More
May 25, 2020
- MSD’s 9-Valent HPV Vaccine Now in Line for June Approval; Eyes on Its Possible Inclusion in National Immunization Program
May 25, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…